Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bonomi

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Statistics in Medicine|April 29, 1998
Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trialsD L Fairclough, H F Peterson, D Cella, et al.
Medical Hypotheses|November 1, 2003
An interaction between type 1 and type 2 programmed cell death and clonogenic survivalK M Anderson, P Bonomi, Y Hu, et al.
The Prostate|January 1, 1985
Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresisK M Anderson, J Baranowski, P Bonomi, et al.
Medical Hypotheses|May 26, 1999
Free radical spin traps as adjuncts for the prevention and treatment of diseaseK M Anderson, G Ells, P Bonomi, et al.
Cancer Research|November 1, 1980
Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancerK M Anderson, P Bonomi, M Marogil, et al.
Gynecologic Oncology|September 1, 1989
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyP Bonomi, J Blessing, H Ball, et al.
Medical and Pediatric Oncology|January 1, 1979
Management of carcinoid syndromeP Bonomi, C Hovey, J R Dainauskas, et al.
Gynecologic Oncology|June 1, 1982
Hypertrophic osteoarthropathy associated with endometrial carcinomaJ Margolick, P Bonomi, E Fordham, et al.
Medical Hypotheses|June 11, 1999
Does maximizing programmed cell death necessarily yield an optimum clinical advantage?D Ou, K M Anderson, W Leslie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatinE K Rowinsky, M Jiroutek, P Bonomi, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Statistics in Medicine|April 29, 1998
Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trialsD L Fairclough, H F Peterson, D Cella, et al.
Medical Hypotheses|November 1, 2003
An interaction between type 1 and type 2 programmed cell death and clonogenic survivalK M Anderson, P Bonomi, Y Hu, et al.
The Prostate|January 1, 1985
Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresisK M Anderson, J Baranowski, P Bonomi, et al.
Medical Hypotheses|May 26, 1999
Free radical spin traps as adjuncts for the prevention and treatment of diseaseK M Anderson, G Ells, P Bonomi, et al.
Cancer Research|November 1, 1980
Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancerK M Anderson, P Bonomi, M Marogil, et al.
Gynecologic Oncology|September 1, 1989
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyP Bonomi, J Blessing, H Ball, et al.
Medical and Pediatric Oncology|January 1, 1979
Management of carcinoid syndromeP Bonomi, C Hovey, J R Dainauskas, et al.
Gynecologic Oncology|June 1, 1982
Hypertrophic osteoarthropathy associated with endometrial carcinomaJ Margolick, P Bonomi, E Fordham, et al.
Medical Hypotheses|June 11, 1999
Does maximizing programmed cell death necessarily yield an optimum clinical advantage?D Ou, K M Anderson, W Leslie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatinE K Rowinsky, M Jiroutek, P Bonomi, et al.
Pageof 10